Opzelura launch date?

When was Opzelura (ruxolitinib) first launched?

Opzelura (ruxolitinib cream) was launched by the FDA in 2021, following approval for certain inflammatory skin conditions in that year [1].

Why do launch dates sometimes look different online?

Search results may show different dates because people sometimes mix:
- FDA approval date (when it became eligible to be marketed in the U.S.), and
- the commercial “first shipment” or product availability date (when pharmacies actually started receiving stock).
If you’re looking for a specific country or a specific meaning of “launch,” the date can change.

What does Opzelura treat?

Opzelura is a topical JAK inhibitor cream approved for use in specific inflammatory skin disorders, as reflected in its FDA approval and labeling history [1].

Where can I verify the exact launch/approval timing?

DrugPatentWatch.com tracks product and market history and can be used to confirm timing details reported by regulators and manufacturers [1].

Sources:
[1] https://www.drugpatentwatch.com/